CommercialCoverageHigh impact
Circulating Tumor-Tissue-Modified Viral DNA Testing for Cancer Management (2.04.160)
Blue Shield of California·CA · Oncology, ENT (Ear, Nose & Throat), Radiation Oncology·Medical Policy
Effective date
Aug 1, 2026
We identified it
Jul 31, 2026
Summary
Blue Shield of California has issued a new medical policy (2.04.160) effective August 1, 2026, designating Circulating Tumor-Tissue-Modified Viral (TTMV) HPV DNA testing (NavDx) as investigational for cancer management. This test cannot be covered for HPV-related head and neck squamous cell carcinoma (HNSCC), anal squamous cell carcinoma (ASCC), or to determine HPV-related cancer status due to insufficient evidence of clinical utility.
Action Required
By August 1, 2026: Billing team must immediately update billing system rules to deny/reject all claims for NavDx and any TTMV-HPV DNA testing under Blue Shield of California Commercial plans. Update claim submission protocols to reflect investigational status classification. Providers and staff must be notified that this test is not covered for any HPV-related cancer indication (HNSCC, ASCC, or HPV status determination). Implement denial message in system: 'Service classified as investigational per Blue Shield Policy 2.04.160.' Any claims submitted for these services will be denied. Do NOT bill these tests to patients as covered benefits; ensure informed consent documents clearly state investigational/non-covered status before any testing.